Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.

Trial Details

NCT ID
NCT02203903
Phase
PHASE1
Sponsor
Catherine Bollard
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Tumor associated antigen lymphocytes (TAA-T)
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • Aged 6 months to 80 years.
  • Anticipated myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant.
  • Patients with high risk AML and MDS who have received or will receive an allo-HSCT and have not had hematologic relapse of disease.
  • Karnofsky/Lansky score of ≥ 50.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →